Human vs Rat race
Looks like recent “clash of Titans” on Care Cure Forum about concept of approach Spinal Cord Injury Recovery models brought more excitment by the end of this year.
We have Dr. Wise Young’s Human Trial with umbilical cord blood stem cells in full swing and Dr. Jerry Silver new delivery method of Enzyme Ch’ase in Rat / Laboratory experiments with promising results.
Both Doctors represent teams with different approach in search for cure of Spinal Cord Injury
and there is no hope for cooperation on horizon.
Looking at tracks from reserved boxes for handicaps we are privileged to cheer and support
both teams in (symplified) Human vs Rat or Stem cells vs. Ch’ase race.
We also hope to see merging of best methods and solutions and more and faster collaboration
but looks like unavoidable to see posssibly fierce competition and real race in the next 6 – 12 months.
Maybe, fast & fierce competition will bring more to the table than slow, too careful collaboration.
Post and Info about Dr. Wise’s trial is here on my Blog.
What the other teams of scientists (one with with Dr. J. Silver) are up to, read below.
It’s known for long time that bacterial enzyme chondroitinase ABC (ChABC) is disolving the “scar” that is forming after Spinal Cord Injury and than inhibit nerve growth and regeneration. The main problem is to deliver this enzyme to injured site as this very unstable substance is quickly disapear affected by normal human body trmperature.
The latest research shows in Rat model that scientists have figure out how to deliver chondroitinase ABC (ChABC) to injured site in one case using Viral and in another case Peptide method. Both researches are the latest news – top of the line findings in fully experimental phase (Rat model} and will be presented in October 2012 Conferences.
There is new hope for the use of viral delivery of ch’ase as a way to treat a much broader area of the cord and for more lengthy time periods. Because contusive lesions are so large simple injection of the enzyme after such injuries has not been very successful. Things are changing now and here is an abstract from the Bradbury lab to explain this new strategy. Gene delivery of chondroitinase ABC promotes functional repair following spinal cord injury
Spinal cord extracellular matrix is densely packed with growth inhibitory chondroitin sulphate proteoglycans (CSPGs), which become more abundant after injury. Thus, matrix modification has become a leading experimental strategy for promoting repair following spinal cord injury. Despite the beneficial effects that have been achieved by digesting CSPGs with the bacterial enzyme chondroitinase ABC (ChABC), the potential for achieving long term efficacy in traumatic injuries that mimic a human spinal cord injury has not yet been released. Gene therapy offers a route to achieving stable continuous delivery of ChABC and therefore, here we deliver genetically modified ChABC via a lentiviral vector (LV-ChABC) to the adult rat spinal cord and assess the efficacy of chronic gene delivery using a spinal contusion injury model.
Dr. Jerry Silver
“We have now constructed the peptide which can be simply injected under the skin or via other potential easy routes of administration. It is designed to penetrate into the CNS even if given systemically. We are doing both acute and, of course, chronic experiments.”